Analgesics in China

Analgesics in China

Systemic analgesics, represented mainly by ibuprofen, witnessed an extraordinary surge in demand in China during the first and second quarters of 2023. This unprecedented growth was a direct consequence of the lifting of lockdown restrictions in the final quarter of 2022. The strong growth of these anti-fever products in Q1 2023 has created a challenge to growth in 2024, and is set to drive a decline in retail current value sales of ibuprofen in this year, and negatively impact the overall perfo...

Euromonitor International's Analgesics in China report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2019-2023, allowing you to identify the sectors driving growth. Forecasts to 2028 illustrate how the market is set to change.

Product coverage: Systemic Analgesics, Topical Analgesics/Anaesthetic.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Analgesics market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.